在日本,使用基于网络的调查评估非全身性青少年异常性关节炎患者的药物戒断情况
Takasuke Ebato1, Takayuki Kishi2, Keiji Akamine3
1Department of Pediatrics, Kitasato University, Kanagawa, Japan.
Modern rheumatology
|March 5, 2024
概括
暂停青少年异常性关节炎 (JIA) 治疗的逐渐减缓策略取决于不活跃的疾病持续时间和药物毒性. 需要仔细考虑风险,以确保安全的JIA药物停用.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 临床药理学 临床药理学
背景情况:
- 青春期异常性关节炎 (JIA) 治疗方法已经进步,但缺乏戒药指南.
- 目前的JIA管理缺乏明确的协议来停止非系统性疗法.
研究的目的:
- 调查目前停止非系统性JIA治疗的策略.
- 确定影响JIA药物减量决策的关键因素.
主要方法:
- 在网上向日本儿科风湿病学协会的成员分发了一份基于网络的问卷.
- 分析了126个反应,以了解治疗逐渐减少的做法.
主要成果:
- 临床不活跃的疾病持续时间 (>12个月),药物毒性和发作史显著影响了JIA治疗的逐渐减少.
- 橄关节性JIA比类风湿因子阳性多关节性JIA更容易逐渐缩小.
- 超过50%的受访者需要超过6个月才能停止治疗,40%的人在逐渐减少之前使用成像.
结论:
- 关于JIA治疗的延续与停止的决定需要仔细评估风险.
- 进一步的研究,包括长期结果,对于最佳和安全的JIA治疗中止策略至关重要.
更多相关视频
02:28Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
383
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
221
相关概念视频
Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Assessment of the Gastrointestinal System I: Subjective Data
194
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
194
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K
